Patents Assigned to F. HOFFMANN-LA ROCHE
-
Patent number: 12296138Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.Type: GrantFiled: September 28, 2018Date of Patent: May 13, 2025Assignees: F. HOFFMANN-LA ROCHE AG, GENENTECH, INC.Inventors: Markus Hemminger, Ulla Grauschopf, Frank Bamberg, Mayumi Bowen, Robert Müller, Flora Felsovalyi, Denny Christensen
-
Patent number: 12220496Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.Type: GrantFiled: June 6, 2023Date of Patent: February 11, 2025Assignees: F. HOFFMANN-LA ROCHE AG, GENENTECH, INC.Inventors: Markus Hemminger, Ulla Grauschopf, Frank Bamberg, Mayumi Bowen, Robert Müller, Flora Felsovalyi, Denny Christensen
-
Publication number: 20240279312Abstract: Composition comprising recombinant Gplb? receptor protein Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib? that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.Type: ApplicationFiled: July 17, 2023Publication date: August 22, 2024Applicant: F. HOFFMANN-LA ROCHE AGInventors: Elizabeth Booth, Virginia Montanini, John A. Hall, Jody Berry
-
Patent number: 11738106Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.Type: GrantFiled: September 28, 2018Date of Patent: August 29, 2023Assignees: F. HOFFMANN-LA ROCHE AG, GENENTECH, INC.Inventors: Markus Hemminger, Ulla Grauschopf, Frank Bamberg, Mayumi Bowen, Robert Müller, Flora Felsovalyi, Denny Christensen
-
Patent number: 11596620Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: GrantFiled: November 22, 2017Date of Patent: March 7, 2023Assignee: F. HOFFMANN-LA ROCHE AGInventors: Sreedhara Alavattam, Mary Mallaney, Parbir Grewal
-
Patent number: 11124563Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.Type: GrantFiled: December 2, 2019Date of Patent: September 21, 2021Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
-
Patent number: 11077132Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: August 3, 2021Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Patent number: 11008394Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.Type: GrantFiled: April 22, 2019Date of Patent: May 18, 2021Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. HOFFMANN-LA ROCHE AGInventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
-
Patent number: 10799523Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: October 13, 2020Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
-
Patent number: 10787505Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).Type: GrantFiled: November 13, 2014Date of Patent: September 29, 2020Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
-
Publication number: 20200253963Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.Type: ApplicationFiled: March 23, 2020Publication date: August 13, 2020Applicants: GENENTECH, INC., F. HOFFMANN-LA ROCHE AGInventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
-
Patent number: 10538582Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.Type: GrantFiled: September 25, 2018Date of Patent: January 21, 2020Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
-
Patent number: 10457648Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.Type: GrantFiled: September 25, 2015Date of Patent: October 29, 2019Assignees: GENENTECH INC., F. HOFFMANN-LA ROCHE AGInventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
-
Patent number: 10168326Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.Type: GrantFiled: March 23, 2016Date of Patent: January 1, 2019Assignee: F. HOFFMANN-LA ROCHE INC.Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
-
Patent number: 10087245Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.Type: GrantFiled: January 28, 2015Date of Patent: October 2, 2018Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
-
Patent number: 10087237Abstract: Herein is reported a method for producing an antibody preparation comprising the steps of a) applying a buffered solution comprising different isoforms of an antibody to a cation exchange chromatography material, b) applying a first solution with a first conductivity to the cation exchange chromatography material, whereby the antibody isoforms remain bound to the cation exchange chromatography material, and c) applying a second solution with a second conductivity to the cation exchange chromatography material and thereby obtaining the antibody preparation, whereby the conductivity of the second solution exceeds the conductivity of the first solution by not more than 10%.Type: GrantFiled: November 6, 2015Date of Patent: October 2, 2018Assignee: F. HOFFMANN-LA ROCHE AGInventors: Roberto Falkenstein, Klaus Schwendner, Bernhard Spensberger
-
Patent number: 9754505Abstract: A method for training staff for quality control when filling amorphous products into primary packaging. The method includes a provision step during which a test set having a plurality of primary packages filled with an amorphous product is provided, wherein at least one of the filled primary packages is afflicted by a contaminant comprising a fluorescent marker. A training step includes presenting the test set to a person to be trained, who carries out a visual quality control for detecting contaminants. The result of the training step is documented. A verification step is conducted during which the test set is irradiated by excitation light, wherein fluorescing contaminants are detected and the result of the verification step is documented. A comparison step is done during which the result of the training step and the result of the verification step are compared. Also disclosed is an inventive test kit and test set.Type: GrantFiled: September 18, 2014Date of Patent: September 5, 2017Assignee: F. HOFFMANN-LA ROCHE AGInventor: Alexandra Ehrhardt
-
Publication number: 20170058022Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.Type: ApplicationFiled: January 28, 2015Publication date: March 2, 2017Applicant: F. HOFFMANN-LA ROCHE AGInventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
-
Publication number: 20160297763Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.Type: ApplicationFiled: April 6, 2016Publication date: October 13, 2016Applicants: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)Inventors: Dirk CLASSEN-HOUBEN, Andrea WOLKERSTORFER, Oliver SZOLAR, Mark SMITH, Sung-Sau SO, Stephen CUSACK, Thierry LANGER, Bruno GIETHLEN, Christophe MORICE, Céline MICHAUT-SIMON, Chloe ZUBIETA
-
Patent number: 9434725Abstract: 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: June 26, 2013Date of Patent: September 6, 2016Assignee: F. HOFFMANN-LA ROCHE AGInventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Vickie H. Tsui, Xiaojing Wang